全文获取类型
收费全文 | 36305篇 |
免费 | 2799篇 |
国内免费 | 380篇 |
专业分类
耳鼻咽喉 | 391篇 |
儿科学 | 991篇 |
妇产科学 | 965篇 |
基础医学 | 4623篇 |
口腔科学 | 596篇 |
临床医学 | 3759篇 |
内科学 | 7700篇 |
皮肤病学 | 845篇 |
神经病学 | 2419篇 |
特种医学 | 1323篇 |
外科学 | 4922篇 |
综合类 | 1294篇 |
一般理论 | 32篇 |
预防医学 | 1986篇 |
眼科学 | 1583篇 |
药学 | 2764篇 |
1篇 | |
中国医学 | 307篇 |
肿瘤学 | 2983篇 |
出版年
2023年 | 270篇 |
2022年 | 511篇 |
2021年 | 962篇 |
2020年 | 618篇 |
2019年 | 781篇 |
2018年 | 1003篇 |
2017年 | 770篇 |
2016年 | 874篇 |
2015年 | 1049篇 |
2014年 | 1383篇 |
2013年 | 1658篇 |
2012年 | 2364篇 |
2011年 | 2470篇 |
2010年 | 1428篇 |
2009年 | 1267篇 |
2008年 | 1936篇 |
2007年 | 2025篇 |
2006年 | 2014篇 |
2005年 | 1939篇 |
2004年 | 1716篇 |
2003年 | 1592篇 |
2002年 | 1423篇 |
2001年 | 1130篇 |
2000年 | 1062篇 |
1999年 | 916篇 |
1998年 | 394篇 |
1997年 | 298篇 |
1996年 | 279篇 |
1995年 | 218篇 |
1994年 | 209篇 |
1993年 | 208篇 |
1992年 | 461篇 |
1991年 | 446篇 |
1990年 | 426篇 |
1989年 | 417篇 |
1988年 | 365篇 |
1987年 | 381篇 |
1986年 | 341篇 |
1985年 | 290篇 |
1984年 | 208篇 |
1983年 | 151篇 |
1982年 | 111篇 |
1981年 | 94篇 |
1980年 | 101篇 |
1979年 | 140篇 |
1978年 | 95篇 |
1977年 | 81篇 |
1976年 | 85篇 |
1975年 | 84篇 |
1972年 | 69篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
992.
993.
Recommendations for future research in relation to pediatric pulmonary embolism: communication from the SSC of the ISTH 下载免费PDF全文
994.
Exploratory study on the relationship between smoking and other risk behaviours among young smokers 下载免费PDF全文
995.
996.
Chien‐Ho Chu M.D. Yu‐Pin Cheng M.D. Jung‐Yi Lisa Chan M.D. 《Pediatric dermatology》2016,33(3):e218-e219
Alopecia areata (AA) is the most common form of hair loss in children. We report the case of a child who had two episodes of AA after two different vaccines with complete hair regrowth between the episodes. This case supports the concept that vaccination might be a trigger for the development of AA in genetically predisposed children. 相似文献
997.
998.
999.
K.A. Papp C.E.M. Griffiths K. Gordon M. Lebwohl P.O. Szapary Y. Wasfi D. Chan M.‐C. Hsu V. Ho P.D. Ghislain B. Strober K. Reich 《The British journal of dermatology》2013,168(4):844-854
Summary Background Long‐term safety evaluations of biologics are needed to inform patient management decisions. Objectives To evaluate the safety of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years. Methods Safety data were pooled from four studies of ustekinumab for psoriasis. Rates of adverse events (AEs), serious AEs (SAEs) and AEs of interest [infections, nonmelanoma skin cancers (NMSCs), other malignancies and major adverse cardiovascular events (MACE)] per 100 patient‐years (PY) of follow‐up were analysed by ustekinumab dose (45 or 90 mg) and by year of follow‐up (years 1–5) to evaluate the dose response and impact of cumulative exposure. Observed rates of overall mortality and other malignancies were compared with those expected in the general U.S. population. Results Analyses included 3117 patients (8998 PY) who received one or more doses of ustekinumab, with 1482 patients treated for ≥ 4 years (including 838 patients ≥ 5 years). At year 5, event rates (45 mg, 90 mg, respectively) for overall AEs (242·6, 225·3), SAEs (7·0, 7·2), serious infections (0·98, 1·19), NMSCs (0·64, 0·44), other malignancies (0·59, 0·61) and MACE (0·56, 0·36) were comparable between dose groups. Year‐to‐year variability was observed, but no increasing trend was evident. Rates of overall mortality and other malignancies were comparable with those expected in the general U.S. population. Conclusions No dose‐related or cumulative toxicity was observed with increasing duration of ustekinumab exposure for up to 5 years. Rates of AEs reported in ustekinumab psoriasis trials are generally comparable with those reported for other biologics approved for the treatment of moderate‐to‐severe psoriasis. 相似文献
1000.